

Date: 22<sup>nd</sup> June, 2018

To, <b>BSE Limited,</b> 25, P. J. Towers, Dalal Street, Mumbai – 400 001 <b>Ref:</b> Company Scrip Code: 532834	To, The Manager, Listing Department, <b>National Stock Exchange of India Ltd.,</b> Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 <b>Ref:</b> Symbol: CAMLINFINE    Series: EQ
--	---

**Sub: Intimation by Camlin Fine Sciences Limited (the “Company”) under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations”)**

Dear Sir/ Madam,


The board of directors of Company (the “Board”) by its resolution dated 24 May 2018 have approved raising of funds by the Company not exceeding Rs. 250 crores by way of *inter alia* debt and foreign currency convertible bonds, global depository receipts, American depository receipts, qualified institutions placement (“**Proposed Fund Raising**”), which was intimated pursuant to our letter dated 24 May 2018. The Proposed Fund Raising has also been approved by the shareholders of the Company at the extra-ordinary general meeting held today on 22nd June, 2018. The Board have delegated powers to the Securities Issue and Allotment Committee to determine inter-alia, the form, the manner and pricing of the proposed securities and/or equity shares to be issued pursuant to the Proposed Fund Raising

In terms of Regulation 29 of the Listing Regulations, this is to inform that a meeting of the Securities Issue and Allotment Committee of the Board is scheduled to be held on or after 27<sup>th</sup> June, 2018 to consider inter-alia the exact mode of Proposed Fund Raising and pricing for equity shares and/or securities to be issued pursuant the Proposed Fund Raising.

We request you to take the above on record and treat it as compliance under the applicable provisions of the Listing Regulations.

Thanking you,

Yours faithfully,  
For **Camlin Fine Sciences Limited**

  
(Rahul D. Sawale)  
Group Company Secretary

